Bioventus Inc. provided preliminary unaudited earnings guidance for the first quarter of 2022. For the period, the company expects net sales to be in the range of $116.5 million to $118.5 million, reflecting 42% to 45% growth over the prior-year period. Net loss expects to be in the range of $19,000,000 and $19,400,000.